

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Ruben et al.

Docket No.: PF526C1N

Application No.: Not Yet Assigned

Filed: Concurrently Herewith

Art Unit: N/A

For: Human Tumor Necrosis Factor TR18 and
Methods Based Thereon

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

MS Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to references A1-43 listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of references A1-A37 on the PTO/SB/08 are not provided. Copies of references A38-A43 are attached herewith.

References A1-A37 in the attached form PTO/SB/08 are not supplied because they were previously cited by or submitted to the Office in prior application number 09/848,271, filed May 4, 2001 and relied upon in this application for an earlier filing date under 35 U.S.C. 120.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this

Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 08-3425.

Dated: Feb. 26, 2004

Respectfully submitted,

By Michele Shannon
Michele Shannon

Registration No.: 47,075
HUMAN GENOME SCIENCES, INC.
14200 Shady Grove Road
Rockville, Maryland 20850
(240) 314-4400 ext. 2372

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Steven M. Ruben
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	PF526C1N

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)					
	A1	WO-01/12812-A2		02-22-2001	Biogen, Inc.		
	A2	WO-01/24811-A1		04-12-2001	Biogen, Inc.		
	A3	WO-00/68378-A1		11-16-2000	National Jewish Medical and Research Center		
	A4	WO-00/40716-A2		07-13-2000	Zymogenetics, Inc.		
	A5	WO-00/40716-A3		07-13-2000	Zymogenetics, Inc.		
	A6	WO-01/60397-A1		08-23-2001	Genentech, Inc.		
	A7	WO-01/75067-A2		10-11-2001	Hyseq, Inc.		
	A8	WO-01/75067-A3		10-11-2001	Hyseq, Inc.		
	A9	WO-00/50633-A1		08-31-2000	The General Hospital Corp.		
	A10	WO-01/87979-A2		11-22-2001	Amgen, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	A11	LAABI et al., Genbank Accession No. NP_00183, (October 31, 2000).	
	A12	CARNINCI et al., Genbank Accession No. NP_035738, (January 07, 2002).	
	A13	LAABI et al., Genbank Accession No. S43486, (January 27, 1995).	
	A14	TSAPIS, A., Genbank Accession No. Z14954, (July 22, 1994).	
	A15	LAABI et al., Genbank Accession No. Z29575, (June 13, 1994).	
	A16	TSAPIS, A., Genbank Accession No. Z14955, (July 26, 1993).	
	A17	LAABI et al., Genbank Accession No. Z29574, (June 25, 1997).	
	A18	LAABI et al., Genbank Accession No. Z29572, (June 13, 1994).	
	A19	BIRREN et al., Genbank Accession No. AC034281, (April 5, 2000).	
	A20	MAHAIRAS et al., Genbank Accession No. AQ182725, (September 9, 1998).	
	A21	LOFTUS et al., Genbank Accession No. U95742, (January 10, 2000).	
	A22	BRUCE et al., Genbank Accession No. AC007216, (January 28, 2000).	
	A23	MARRA et al., Genbank Accession No. AA989895, (June 02, 1998).	
	A24	WINTERO et al., Genbank Accession No. Z81277, (October 24, 1996).	
	A25	BONALDO et al., Genbank Accession No. AI044213, (February 11, 1999).	
	A26	LAABI et al., Genbank Accession No. NM_001192, (March 24, 1999).	
	A27	NCI-CGAP, Genbank Accession No. AA286974, (August 15, 1997).	
	A28	NCI-CGAP, Genbank Accession No. AW139591, (October 30, 1999).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Steven M. Ruben
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	PF526C1N
Sheet	2	of	2		

A29	NCI-CGAP, Genbank Accession No. AA258846, (August 13, 1997).	
A30	NCI-CGAP, Genbank Accession No. AI865358, (December 21, 1999).	
A31	NCI-CGAP, Genbank Accession No. AA286871, (August 14, 1997).	
A32	NCI-CGAP, Genbank Accession No. AA633372, (October 28, 1997).	
A33	NCI-CGAP, Genbank Accession No. AA259026, (August 13, 1997).	
A34	NCI-CGAP, Genbank Accession No. AA743176, (January 27, 1998).	
A35	NCI-CGAP, Genbank Accession No. AA987627, (July 27, 1998).	
A36	LAABI et al., Nucleic Acid Research, Vol. 22, No. 7, pages 1147-1154, 1994.	
A37	LOCKSLEY et al., "The TNF and TNF Receptor Superfamilies: Integrating Mammalian Biology," Cell, Vol. 104, pages 487-501, February 2001.	
A38	BERKOW, R. et al. (eds.), "The Merck Manual of Diagnosis and Therapy, (Fifteenth Edition), " Merck & Co., Inc., NJ, at pages 319 to 322 (1987).	
A39	BERKOW, R. et al. (eds.), "The Merck Manual of Diagnosis and Therapy, (Fifteenth Edition), " Merck & Co., Inc., NJ, at pages 1249 to 1250 (1987).	
A40	GenBank Accession No. NP_006564, (October 7, 2002).	
A41	Ebner et al., Geneseq Database Accession No. AAW58391, (May 7, 1998).	
A42	Groom et al., "Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome," J. Clin. Invest. (2002) 109:59-68	
A43	Mariette et al., "The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome," Ann. Rheum. Dis. (2002) 62:168-171	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--